HVTN 144
enrollment full
(ClinicalTrials.gov link: NCT06033209)
This is a Phase 1 study of an investigational vaccine and an adjuvant (a compound added to heighten immune response). The study vaccine includes a man-made protein that looks like a protein found on the outside of HIV.
Study vaccines used in this study are not made from live or killed HIV. These study vaccines cannot cause HIV infection or AIDS.
This study will enroll 84 participants who are in overall good health and between 18 and 55 years old. It will look at different doses of the study products and different ways of giving the products and different routes of giving the injections to see how these factors change the immune response.
Eligibility criteria:
- HIV-negative;
- Between 18–55 years old;
- In good general health.
HVTN 313– Fusion Peptide Vaccine Study
enrollment full
ClinicalTrials.gov link: NCT06332339
This study is investigating three vaccines. Two of the vaccines are protein vaccines made to resemble a piece of protein on the surface of HIV. The third vaccine is an intranasal vaccine, made using an adenovirus; adenoviruses e viruses that cause illnesses like the common cold.
Because adenoviruses can be contagious, household contacts of participants are also invited to join the study for follow-up. Household contacts must be over the age of 18 and not be immunocompromised.
Study vaccines used in this study are not made from live or killed HIV. These study vaccines cannot cause HIV infection or AIDS.
Eligibility criteria:
- HIV-negative;
- Between 18–55 years old;
- BMI < 40; and
- In good general health.
